Neuroone Medical Technologies (NMTC) investor relations material

Technology overview and product portfolio

• Developed a thin film electrode platform for diagnostic and therapeutic use in neurological conditions, including epilepsy, Parkinson's, back pain, and drug delivery.

• Four devices have FDA 510(k) clearance; three for brain applications and one for facial pain.

• Partnerships with Mayo Clinic and Zimmer Biomet support device testing, distribution, and robotic placement.

• The OneRF Ablation System is the only FDA-cleared device for both diagnostic and therapeutic brain use, driving most revenue.

• Registry established to collect and publish real-world outcomes, with strong safety and efficacy data reported.

Market opportunity and commercialization

• Devices target multi-billion dollar markets, with spinal cord stimulation alone generating $3–4 billion annually.

• International expansion planned, with ISO 13485 certification in progress to enable overseas distribution.

• Drug delivery device supports gene/cell therapy development and can be used from preclinical to commercial stages.

• Ongoing discussions for new partnerships in pain management and drug delivery, with potential deals expected in 2026.

• Full launch of trigeminal nerve ablation system anticipated next quarter, following successful limited market release.

Financial performance and outlook

• As of December 31, cash on hand was $3.6 million, with $2.7 million in receivables since collected and no debt.

• Fiscal Q1 product revenue reached $2.9 million, up 5.5% sequentially, with a 54.2% gross margin.

• Projected FY revenue of at least $10.5 million, a minimum 17% increase year-over-year.

• Current cash runway extends through September 2026, not including potential partnership proceeds.

• International revenue expected to begin after ISO certification, likely in the next fiscal year.